BOTANIQUE Reformulates Major Products from CBN to CBG
BOTANIQUE, a biotech startup specializing in research and commercialization of new materials, has reformulated its key products from CBN (Cannabinol) to CBG (Cannabigerol). The company successfully raised approximately ¥150 million in Series A funding in May 2022 and has experience in researching nano CBD formulations that drastically improve CBD absorption efficiency and supplying CBD products to over 500 locations nationwide, including medical institutions.
📋 Article Processing Timeline
- 📰 Published: April 17, 2026 at 09:00
- 🔍 Collected: April 17, 2026 at 09:31 (31 min after Published)
- 🤖 AI Analyzed: April 18, 2026 at 20:44 (35h 12m after Collected)
A biotech startup engaged in the research and commercialization of new materials. In addition to planning and developing over 200 CBD products, we have succeeded in research on nano CBD formulations that drastically improve CBD absorption efficiency, a first in the industry. In May 2022, we raised approximately ¥150 million in Series A funding. We have already distributed CBD products to over 500 locations nationwide, including medical institutions.